跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NL-OMON44322
NL-OMON44322已完成不适用

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer. - M14-361

AbbVie B.V.0 个研究点目标入组 19 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AbbVie B.V.
入组人数
19
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99（—）

入选标准

  • •1. Subject with histologically or cytologically confirmed extensive stage SCLC which is newly diagnosed and chemotherapy naïve.;2. Phase 1 ONLY: histologically or cytologically confirmed advanced/metastatic solid tumors for which carboplatin/etoposide treatment is considered appropriate.;3. Subject in Phase 2 only: must have measureable disease per RECIST 1.1.;4. Subjects with ED SCLC must consent to provide available archived formalin fixed paraffin embedded (FFPE) tissue sample of SCLC lesion (primary or metastatic) for central review and biomarker analysis.;5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1.;6. Subject must be >= 18 years of age.;7. Subject must have adequate hematologic, renal and hepatic function as follows:
  • •Bone Marrow: Absolute neutrophil count ANC >= 1,500/mm3 (1.5 × 10e9/L); White blood cells >= 3,000/mm3 (3 × 10e9/L); Platelets >= 100,000/mm3 (100 × 10e9/L); Hemoglobin >= 9 g/dL (5.58 mmol/L)
  • •Renal function: creatinine <= ULN or if creatinine > ULN calculated creatinine clearance via the Cockroft Gault formula of >= 50 mL/min
  • •Hepatic function:
  • •- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 × upper limits of normal (ULN). For subjects with liver metastases, AST and ALT <= 5 × ULN;
  • •- Bilirubin: <= 1.5 × ULN; for subjects with Gilbert's syndrome bilirubin > 1.5 × ULN is allowed if no symptoms of compromised liver function are present.;8. Subject must be able to swallow pills.;9. Female and male patients of fertile age, and/or their partners should use contraception. If male, subject and subject's female partner(s) of childbearing potential should practice at least one of the following methods of birth control. If female, subject must be either postmenopausal for at least 1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or the subject and the subject's male partner(s) practicing at least one of the following methods of birth control:
  • •total abstinence from sexual intercourse (if it is the subject's preferred and usual lifestyle; for minimum one complete menstrual cycle prior to study drug administration and to extend 6 months after treatment);
  • •vasectomized subject or partner(s);
  • •hormonal contraceptives (oral, parenteral or transdermal) for at least 90 days prior to study drug administration for the subject or subject's female partner(s);
  • •intrauterine device (IUD) for the subject or subject's female partner(s); or
  • •double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with (spermicidal jellies or creams) for the subject or subject's female partner(s). ;If hormonal contraceptives are used, the specific contraceptive must have been used for at least 90 days prior to study drug administration. If the subject or subject's female partner(s) is currently using a hormonal contraceptive, she should also use a barrier method during this study and for 6 months (or per local label) after study completion. ;Female subjects must have negative results for pregnancy tests performed:
  • •at Screening on a serum specimen obtained within 7 days prior to initial study drug administration, and
  • •prior to dosing on a urine sample obtained C1D-2 unless the serum pregnancy test was collected within 7 days of C1D-2. ;10. Must voluntarily sign and date each informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Rev

排除标准

  • •1. Phase 1 ONLY: Subject has had any prior anti-cancer therapy other than:
  • •* Hormonal, non-myelosuppressive, biologic, targeted, or immune therapy (must be completed >= 4 weeks prior to Cycle 1 Day -2).
  • •* One line of cytotoxic chemotherapy (must be completed >= 4 weeks prior to Cycle 1 Day -2).
  • •* Adjuvant/neoaduvant radiotherapy (must be completed >= 12 months prior to Cycle 1 Day -2, with field not involving > 10% of bone marrow reserve).;2. Phase 2 ONLY: Subject has had any prior chemotherapy, radiotherapy, investigational anti-cancer agents or biologic therapy for the disease under study. Single non-target lesion irradiation with intent of symptom palliation is allowed if >= 2 weeks prior Cycle 1 Day -2.;3. Subject has known hypersensitivity to etoposide, platinum compounds or veliparib.;4. Phase 1 ONLY: Subject has received prior myelopoietic growth factors.;5. Subject has current central nervous system (CNS) or leptomeningeal metastases or history of CNS or leptomeningeal metastases. If CNS progression is suspected, a head CT should be performed at screening.;6. Subject has a history of seizures within 12 months of Cycle 1 Day -2 or diagnosed neurological
  • •condition placing subject at the increased risk of seizures.;7. Subject has received traditional herbal anti-cancer medicine (e.g. Chinese, Asian, etc) within 14 days prior to Cycle 1 Day -2.;8. Subject has had major surgery within 6 weeks prior to Cycle 1 Day -2 (subjects must have
  • •completely recovered from any previous surgery prior to Cycle 1 Day -2).;9. Subject has clinically significant and uncontrolled major medical condition(s) including but not
  • •limited to:
  • •* Uncontrolled nausea/vomiting/diarrhea;
  • •* Active uncontrolled infection;
  • •* History of hepatitis B (HBV) with surface antigen (HBsAg) positivity within 3 months prior to
  • •the date of informed consent for this study (if no test has been performed within 3 months, it
  • •must be done at screening);
  • •* History of hepatitis C (HCV) with HCV RNA positivity within 3 months prior to the date of
  • •informed consent for this study (if no test has been performed within 3 months it must be done
  • •at screening);
  • •* Symptomatic congestive heart failure (New York Heart Association [NYHA] class >= II);
  • •* Unstable angina pectoris or cardiac arrhythmia;
  • •* Psychiatric illness/social situation that would limit compliance with study requirements;
  • •* Any other medical condition, which in the opinion of the Investigator, places the subject at an
  • •unacceptably high risk for toxicities.;10. Subject is pregnant or lactating.;11. The subject has a history of another active cancer within the past 3 years except cervical cancer in situ, in situ carcinoma of the bladder, squamous or basal cell carcinoma of the skin or another in situ cancer that is considered cured by the investigator (e.g., in situ prostate cancer, breast ductal carcinoma in situ [DCIS]).

研究者

发起方
AbbVie B.V.

相似试验

进行中（未招募）
1 期
A Phase 1 dose-finding and Phase 2 randomized double-blinded study evaluating if veliparib compared to placebo improves efficacy of caboplatin and etoposide combination in patients with untreated extensive stage small cell lung cancerExtensive Stage Disease Small Cell Lung Cancer (ED SCLC)MedDRA version: 17.0 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-001764-35-ESAbbVie Deutschland GmbH & Co. KG75
进行中（未招募）
1 期
A Phase 1 dose-finding and Phase 2 randomized double-blinded study evaluating if veliparib compared to placebo improves efficacy of caboplatin and etoposide combination in patients with untreated extensive stage small cell lung cancerExtensive Stage Disease Small Cell Lung Cancer (ED SCLC)MedDRA version: 19.0 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-001764-35-FRAbbVie Deutschland GmbH & Co. KG215
进行中（未招募）
1 期
A Phase 1 dose-finding and Phase 2 randomized double-blinded study evaluating if veliparib compared to placebo improves efficacy of caboplatin and etoposide combination in patients with untreated extensive stage small cell lung cancerExtensive Stage Disease Small Cell Lung Cancer (ED SCLC)MedDRA version: 19.0Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-001764-35-CZAbbVie Deutschland GmbH & Co. KG180
进行中（未招募）
1 期
A Phase 1 dose-finding and Phase 2 randomized double-blinded study evaluating if veliparib compared to placebo improves efficacy of caboplatin and etoposide combination in patients with untreated extensive stage small cell lung cancerExtensive Stage Disease Small Cell Lung Cancer (ED SCLC)MedDRA version: 20.0 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-001764-35-BEAbbVie Deutschland GmbH & Co. KG180
进行中（未招募）
1 期
A Phase 1 dose-finding and Phase 2 randomized double-blinded study evaluating if veliparib compared to placebo improves efficacy of caboplatin and etoposide combination in patients with untreated extensive stage small cell lung cancer
EUCTR2014-001764-35-NLAbbVie Deutschland GmbH & Co. KG221
A Phase 1 Dose Escalation and Phase 2 Randomized... | 临床试验